GALVmed aims to make a significant contribution towards transformational change in the small-scale livestock health landscape by developing a portfolio of high impact products and initiating a range of private sector market initiatives operating at scale in the smallholder sector.
About usWe’re excited to share GALVmed’s 2025 Year in Review, an overview of our accomplishments and the progress made throughout the year in advancing our mission.
The review reflects a year of meaningful impact and our continued commitment to strengthening livelihoods through improved livestock health.
Read it here.
GALVmed CEO Dr Lois Muraguri highlights how harmonised regulation will help ensure that safe and effective veterinary medicines and products reach the people who need them most, while also making the market more predictable for both manufacturers and regulators.
The proposed Pan-African Regulatory Authorities Network for Veterinary Products (PARAN-VPs) will guide continental cooperation on veterinary product regulation. It will serve as a continental platform for regulatory cooperation, helping countries align standards, share information and strengthen oversight of veterinary medicines.
Transformational improvement in the well-being and economic progression of small-scale livestock producers.
We will contribute to the transformation of small-scale livestock producers’ lives by:
Product development
GALVmed specialises in product development partnerships uniquely established to translate global research progress into tangible livestock disease control tools for the developing world.
Commercial development
Our work with our partners supports the small-scale livestock producers of the world.
Enabling environment
An enabling environment that allows for the successful translation of research products to sustainable animal health solutions for small scale livestock producers is essential to achieving GALVmed’s mission.
2026-01-29
The candidate vaccine is a novel target identified on the surface of haemorrhagic septicaemia-associated strains of Pasteurella multocida. It has demonstrated robust protection in cattle against lethal challenge with the two serogroups of Pasteurella responsible for HS.
Applying a gender lens to livestock programmes is not an optional add-on, but a strategic necessity. VITAL 2 is a gender-intentional investment, designed to ensure that gender-related barriers and norms are identified and addressed so that women are not excluded from the benefits of ruminant vaccination as markets and delivery systems expand.
Over the years, GALVmed through its partners, has implemented impactful programmes across Africa and South Asia, leading to significant achievements.
The candidate vaccine is a novel target identified on the surface of haemorrhagic septicaemia-associated strains of Pasteurella multocida. It has demonstrated robust protection in cattle against lethal challenge with the two serogroups of Pasteurella responsible for HS.
Applying a gender lens to livestock programmes is not an optional add-on, but a strategic necessity. VITAL 2 is a gender-intentional investment, designed to ensure that gender-related barriers and norms are identified and addressed so that women are not excluded from the benefits of ruminant vaccination as markets and delivery systems expand.
Over the years, GALVmed through its partners, has implemented impactful programmes across Africa and South Asia, leading to significant achievements.
If Africa can mobilise the investments needed to eliminate sleeping sickness in people, it can and must show the same commitment to protecting the animals that sustain its economy.
Imagine that over the course of 10 days, 80 per cent of your livelihood is destroyed. This is a reality for millions of small-scale producers in Africa who depend on sheep and goats for income, nutrition and survival, but have to contend with Peste des Petits Ruminants (PPR), a highly contagious disease with a mortality rate of up to 90 per cent.